The poll found that 82% of Republicans, 92% of Democrats, and 91% of Independents polled supported legislation to limit nonmedical switching.
WPA Intelligence, a national polling organization, recently conducted a telephone poll among 500 likely Texas voters from August 27, 2018 to August 29, 2018 to determine the importance of a candidate’s views on nonmedical switching before casting a vote.
Nonmedical switching is used by insurers to limit prescribing to preferred medications. These changes to a patient’s medication—including, in some cases, a switch from a reference biologic to a biosimilar—can particularly impact patients with chronic conditions who are controlling their disease on a given regimen.
Learn more about nonmedical switching and biosimilars.
WPA Intelligence randomly selected a sample of likely voters from the Texas voter file using Proportionate Probability Sampling. Additionally, the sample for the survey was stratified based on geography, age, and gender.
The poll revealed that the majority of people want consistent health plan coverage for their prescription medications, and are in fact more likely to support legislators who will protect that coverage.
Specifically, the poll found that:
The report also noted that concerns about nonmedical switching were not limited to any specific party, as 82% of Republicans, 92% of Democrats, and 91% of Independents polled supported legislation to limit nonmedical switching.
Nonmedical switching has garnered more attention from legislators and voters alike as several states have enacted or are considering enacting laws to address the practice.
The most recent states to act against nonmedical switching include Maine, which in July passed a law that requires insurers to give 60 days’ notice to affected patients before changing its formulary, and notify patients of their right to request exemptions. Illinois passed a law just last month that similarly requires insurers notify patients and provide details about the exemption process.
Challenges and Guidance in Biosimilar Assessment: An ISPOR Report on HTA Agency Approaches
May 14th 2024The ISPOR report highlights the urgent need for clear guidance on when and how to conduct health technology assessments (HTAs) for biosimilars, emphasizing the challenges faced by HTA agencies and the evolving role of HTAs in evaluating biosimilar value.
Biosimilars Policy Roundup for April 2024—Podcast Edition
May 5th 2024On this episode of Not So Different, The Center for Biosimilars® glances back at all the major biosimilar policy updates from April, including 2 FDA approvals, 1 European approval, and several insights into possible policy changes from the Festival of Biologics USA conference.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Dr Sophia Humphreys Provides Calls to Action to Ensure Biosimilar Market Sustainability
April 30th 2024During her presentation during Festival of Biologics USA, Sophia Humphreys, PharmD, director of formulary management at Sutter Health, gave an overview of current challenges and opportunities for the biosimilar market and offered calls to action for multiple stakeholders.